EVIDENCE-BASED PREVENTIVE MEDICINE • CLINICAL METHODOLOGY

Rigorous clinical validation, transparent algorithmic reasoning.

Built in collaboration with leading longevity physicians, epidemiologists, and computational biologists. Every correlation is cited, quantified, and benchmarked against peer-reviewed clinical trials.

Correlation Accuracy verified
94.2% Sensitivity / Specificity Matrix
95% CI: [92.8% – 95.6%]
Cohort Validation groups
n = 2,400 Tri-center Longitudinal Trial
Follow-up: 36 mos duration
Algorithmic Models schema
840+ Multi-Omic Bayes Kernels
Deterministic rule trees
Indexed References menu_book
12,000+ PubMed & Cochrane Verified
Continuous API ingest pipeline
Clinical Study Archive

Featured Multi-Omic Cohort Study

Download Full Clinical Study PDF (24 pages) arrow_forward
PEER-REVIEWED J. TRANSLATIONAL LONGEVITY 2025 DOI: 10.1038/s41598-025-01449-x

Longitudinal Multi-Omic Biometric Profiling in Early Detection of Subclinical Metabolic Drift

Evaluating the efficacy of continuous autonomous biomarker inference engines in flagging impaired fasting glucose, microvascular arterial stiffness, and occult systemic inflammation up to 28 months prior to primary standard-of-care diagnosis.

Methodology

Continuous CGM + high-density quarterly metabolomics assay

Cohort Demographics

n=2,400 (ages 28–74, balanced distribution across 3 academic medical centers)

Primary Endpoint

Detection of pre-diabetic drift before HbA1c elevation (>5.7%)

insights
Clinical Conclusion

Meridian algorithmic stratification isolated early metabolic divergence with a hazard ratio (HR) of 3.42 (95% CI 2.88–4.06, p < 0.0001) relative to conventional annual wellness panels, conferring an average therapeutic intervention runway of 840 days.

Receiver Operating Characteristic ROC AUC = 0.941 • p < 0.0001
AUC 0.94
0.0 0.5 1.0 0.0 0.5 1.0 Sensitivity: 94.2% Specificity: 91.0%
Meridian Longitudinal Model (0.94)
Standard Baseline (0.72)
Zero-Hallucination Architecture

Deterministic clinical engines, not generative speculation.

Meridian enforces a strict mathematical guarantee: no generative LLM ever formulates diagnostic output. Recommendations are governed by supervised Bayesian belief networks and verified clinical pathways mapped directly to NIH, ACC/AHA, and Endocrine Society thresholds.

Algorithmic Correlation Trace: Scenario #881-A Subject: Male, 46 yrs • Continuous Telemetry & Venous Blood Chemistry
Live Pipeline Verified
01 / INGESTION sensors

Raw Multi-Signal Telemetry

Concurrent identification of diverging physiological vectors:

hs-CRP 2.8 mg/L ↑
Nocturnal HRV 24 ms (14-day ↓)
Fasting Insulin 11.4 μIU/mL
Status: Telemetry Ingested
02 / FILTERING filter_alt

Confounding Factor Pruning

Algorithmic exclusion of benign transient causes via behavioral sync:

  • check Acute infection/rhinovirus: Excluded
  • check Overtraining syndrome: Excluded
  • check Ethanol perturbation: Excluded
Deterministic rules: PASS
03 / INFERENCE calculate

Bayesian Network Evaluation

Calculates likelihood against longitudinal multi-center historical registry:

Hypothesis Subclinical Endothelial Stress
Confidence P-Val p < 0.001
Probability Index 92.4% certainty
Monte Carlo runs: 10,000
04 / INTERVENTION verified

Peer-Reviewed Protocol Output

Generates cited physician directive without speculative language:

Protocol #CVD-208

Target ApoB titration < 60 mg/dL + nocturnal recovery modification.

Ref: Ridker PM et al., NEJM 2017; JAMA Cardiol 2023.
Physician-Ready Sign-off
Scientific Governance

Guided by premier clinical investigators.

Our methodology is audited quarterly by practicing clinicians and bioinformaticians from the world's foremost medical research centers.

Dr. Aris Thorne, MD, PhD

Chief Medical Officer Former Harvard Medical School Fellow

Specialist in molecular hallmarks of cellular senescence and continuous biomarker stratification. Over 40 published studies in cellular longevity.

H-Index: 48 • 6,400+ Citations open_in_new

Dr. Elena Rostova, MD

Cardiovascular Biomarkers Stanford Medicine Preventive Cardiology

Pioneer in non-invasive microvascular monitoring and longitudinal lipid subfraction tracking for early coronary arterial calcification arrest.

AHA Chair Fellow • Stanford open_in_new

Marcus Vance, PhD

Computational Biology MIT Health Sciences & Technology

Architect of multi-omic Bayesian networks and deterministic causal inference engines. Specializes in statistical modeling of subclinical physiological anomalies.

Lead Author: Nature Biotech '24 open_in_new

Dr. Priya K., MD

Early Biomarker Detection Dana-Farber Cancer Institute

Clinical researcher evaluating circulating cell-free methylated DNA markers and systemic inflammatory baselines in early somatic transformation.

Principal Investigator • DFCI open_in_new
Protocol Integrity

Research Ethics & Governance Charter

Biomarker intelligence demands uncompromising governance. Meridian guarantees patient-sovereign control through mathematically verifiable protocols.

IRB Compliance Protocol: #MED-IRB-2024-91
Federal Wide Assurance (FWA): #00029311
01

No Black-Box AI Models

Every inference score is traceable to explicit mathematical coefficients. Clinicians can inspect each Bayesian conditional node directly in the Meridian audit console.

02

Physician-in-the-Loop Safeguards

High-variance biomarker anomalies trigger mandatory asynchronous physician reviews before patient-facing notifications are delivered, preventing panic.

03

Zero-Knowledge Cryptography

Biometric telemetry is encrypted client-side using zk-SNARK protocols. Algorithms execute on obfuscated payloads; personal identities remain segregated at all times.

04

Open Academic Sharing

De-identified population-level drift statistics are made available freely to accredited universities and researchers via our public Academic API endpoint.

Empirical Longevity Infrastructure

Review the science behind predictive longevity.

Access our comprehensive 120-page clinical dossier, full methodology datasets, and peer-reviewed ROC calibration curves.